InvestorQ : InvestorQ-Ask,Answer & Share All About Finance!
diksha shah made post

How significant is the latest approval for Biocon for COVID-19 drug?

Answer
user profile image
Anu Biswas answered.
3 weeks ago


It may be noted that Biocon has secured regulatory nod to use the drug, Itolizumab, on COVID-19 patients. This drug is currently used to cure respiratory problems as well as psoriasis, a skin related disease. The DCGI has given this approval based on randomized trials wherein patients who were administered Itolizumab had responded positively.

Biocon’s Itolizumab is expected to reduce mortality in COVID-19 patients. The urgency to find a reliable cure has been growing as India is adding nearly 27,000 cases on a daily basis. In terms of number of casualties, India is already ranked third in the global list after the United States and Brazil. That makes any progress on these lines very significant.